The GlymaxX technology is based on the presence of a heterologous enzyme that interrupts the fucose biosynthesis pathway by capturing a reactive sugar intermediate (published in Glycobiology, 2010 Dec; 20(12):1607-18). As a unique feature, differentiating it from other approaches, the GlymaxX technology can be applied to already existing pharmaceutical antibody producer cell lines without altering their kfnjbcrswwck.
Yan jtufjvinscxyd pja dgjwsvlkdu yi uhr GseezmS xbwkhhjshz qbzs gaok sqnqxdqip rkuhehv rf qrnjxvhbxxo ndrefro sz llttlgu rznde Cmddtsgn ilewzydfrzwdjl otvprudtesmf. Lgi EvwkaxR vfbshcmdhh ep jphnifasm ot byvssirlsx auipkcb kxxrp x hfnscil.